Works on small‑molecule inhibitors of DNA repair to improve cancer therapy. Combines design and synthesis with structure–activity mapping and docking, validating in human cells to develop selective modulators of key targets (including TDP1/TDP2 and PARP1/2) that sensitize tumors to existing regimens.